(UroToday.com) At the metastatic prostate cancer session at the European Association of Urology 2021 annual meeting, Dr. Giuseppe Fallara discussed the impact of time on treatment with abiraterone or enzalutamide among men with metastatic castration resistant prostate cancer (mCRPC). To date, there are little real-world data on the time of treatment with abiraterone and enzalutamide in men with mCRPC. The objective of this study was to assess time on treatment with abiraterone and enzalutamide from population-based data and to compare it with that reported in randomized control trials.